Plasma concentrations of glucagon-like peptide-2 in adult patients with treated and untreated coeliac disease

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 2, 2006, Pages 195-202

  Caddy, Grant R ^a,b,c   Ardill, Joy E S ^a   Fillmore, Davina ^a   Caldwell, Carolyn M ^a   McKibben, Bronac M ^b   Gardiner, Keith R ^a   Watson, Peter R G ^a,b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ULSTER HOSPITAL   (United Kingdom)

Author keywords

Coeliac disease; Glucagon like peptide 2; Gut glucagon like immunoreactivity; Sprue

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUTEN;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CELIAC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUTEN FREE DIET; HUMAN; MALE; PLASMA; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TREATMENT OUTCOME;

ADULT; CELIAC DISEASE; FEMALE; FOLLOW-UP STUDIES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; GLUCAGON-LIKE PEPTIDES; GLUTEN; HUMANS; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; TREATMENT OUTCOME;

EID: 33644836827     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200602000-00013     Document Type: Article

References (30)

1. Johnston SD, Watson RG, McMillan SA, Sloan J, Love AH. Coeliac disease detected by screening is not silent - simply unrecognised. Q J Med 1998; 91:853-860.
2. Paulley LW. Observations on the aetiology of idiopathic steatorrhoea. BMJ 1954; 2:1318-1321.
3. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983; 304:368-371.
4. Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 1996; 10:342-355.
5. Drucker DJ. Gut adaptation and the glucagon-like peptides. Gut 2002; 50:428-435.
6. Larsson LI, Holst J, Hakanson R, Sundler F. Distribution and properties of glucagon immunoreactivity in the digestive tract of various mammals: an immunohistochemical and immunochemical study. Histochemistry 1975; 44:281-290.
7. Caddy G, Johnston C, Ardill J, Pogue K, Collins J, Gardiner K, et al. Distribution of glucagon-like peptide-2 in normal colonic tissue. Scand J Gastroenterol 2003; 38:798-799.
8. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 1999; 117:99-105.
9. Unger RH, Ketterer H, Eisentraut AM. Distribution of immunoassayable glucagon in gastrointestinal tissues. Metabolism 1966; 15:865-867.
10. Drucker DJ. Glucagon-like peptide 2. Trends Endocrinol Metab 1999; 10:153-156.
11. Besterman HS, Bloom SR, Sarson DL, Blackburn AM, Johnston DI, Patel HR, et al. Gut-hormone profile in coeliac disease. Lancet 1978; 1:785-788.
12. 2 Carson DJ, Glasgow JF, Buchanan KD, Sloan JM. Changes in N-terminal glucagon-like immunoreactivity and insulin during short-term gluten challenge in childhood coeliac disease. Gut 1981; 22:554-557.
13. Kilander AF, Dotevall G, Lindstedt G, Lundberg PA. Plasma enteroglucagon related to malabsorption in coeliac disease. Gut 1984; 25:629-635.
14. Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47:159-169.
15. Flanagan RWJ, Buchanan KD, Murphy RF. Specificity of antibodies in the radioimmunoassay of glucagon. Diabetologia 1974; 10:365-370.
16. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2] GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999; 276:G79-G91.
17. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology; 120:806-815.
18. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999; 277:E937-E947.
19. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001; 61: 687-693.
20. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000; 47:112-119.
21. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93:7911-7916.
22. Drucker DJ, DeForest L, Brubaker PL. Intestinal response to growth factors administered alone or in combination with human [Gly2] glucagon-like peptide 2. Am J Physiol 1997; 273:G1252-G1262.
23. Merger M, Viney JL, Borojevic R, Steele-Norwood D, Zhou P, Clark DA, et al. Defining the roles of perform, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine. Gut 2002; 51:155-163.
24. Kilander AF, Stenhammar L, Undstedt G, Lundberg PA. Determination of enteroglucagon in plasma for detection of celiac disease in children. Clin Chem 1984; 30:77-80.
25. Stenhammar L, Stromberg L, Kilander AF, Lindstedt G, Lundberg PA. Plasma enteroglucagon in the control of childhood celiac disease. J Pediatr Gastroenterol Nutr 1985; 4:325-330.
26. Wahab PJ, Meijer JW, Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathot 2002; 118:459-463.
27. Sategna-Guidetti C, Grosso S, Bruno M, Grosso SB. Reliability of immunologic markers of celiac sprue in the assessment of mucosal recovery after gluten withdrawal. J Clin Gastroenterol 1996; 23:101-104.
28. Jeppesen PB, Hartmann B, Thulesen J, Hansen BS, Holst JJ, Poulsen SS. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000; 47:370-376.
29. Xiao Q, Boushey RP, Cino M, Drucker DJ, Brubaker PL. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol 2000; 278:R1057-R1063.
30. Fraker PJ, Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramide 1,3,4,6-tetrachloro-3alpha, 6alpha- diphenylglycoluril. Biochem Biophys Res Commun 1978; 80:849-857.